E D Hsi

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory
    E D Hsi
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Pathol Lab Med 125:289-94. 2001
  2. ncbi request reprint Flow cytometric analysis of cerebrospinal fluid has low diagnostic yield in samples without atypical morphology or prior history of hematologic malignancy
    Angela M B Collie
    9500 Euclid Ave, Mail Code L11, Cleveland, OH 44195
    Am J Clin Pathol 141:515-21. 2014
  3. doi request reprint MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders
    Sarah L Ondrejka
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Pathol 140:387-94. 2013
  4. ncbi request reprint Pathologic and molecular genetic features of chronic lymphocytic leukemia
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:74-9. 2012
  5. pmc Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
    BMC Cancer 10:387. 2010
  6. ncbi request reprint Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification
    Eric D Hsi
    Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Clin Lymphoma 5:89-97. 2004
  7. ncbi request reprint Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologist
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Pathol Lab Med 126:902-8. 2002
  8. ncbi request reprint Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Br J Haematol 120:1017-25. 2003
  9. ncbi request reprint The leukemias of mature lymphocytes
    Eric D Hsi
    Section of Hematopathology, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 23:843-71. 2009
  10. pmc Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:2081-90. 2008

Detail Information

Publications72

  1. ncbi request reprint A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory
    E D Hsi
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Pathol Lab Med 125:289-94. 2001
    ..Issues relating to regulatory developments, antibody selection, staining optimization, and test validation are addressed...
  2. ncbi request reprint Flow cytometric analysis of cerebrospinal fluid has low diagnostic yield in samples without atypical morphology or prior history of hematologic malignancy
    Angela M B Collie
    9500 Euclid Ave, Mail Code L11, Cleveland, OH 44195
    Am J Clin Pathol 141:515-21. 2014
    ..To identify pretest characteristics of cerebrospinal fluid (CSF) specimens that will allow the rational use of flow cytometric analysis (FCA) in the diagnosis of hematologic malignancy...
  3. doi request reprint MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders
    Sarah L Ondrejka
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Pathol 140:387-94. 2013
    ..To examine the usefulness of the MYD88 L265P somatic mutation in identifying cases of lymphoplasmacytic lymphoma (LPL) from other lymphoplasmacytic neoplasms in bone marrow biopsy specimens...
  4. ncbi request reprint Pathologic and molecular genetic features of chronic lymphocytic leukemia
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:74-9. 2012
    ..Here, we will review the morphologic, immunophenotypic, and molecular genetic features of CLL and touch upon the concept of monoclonal B-cell lymphocytosis...
  5. pmc Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
    BMC Cancer 10:387. 2010
    ....
  6. ncbi request reprint Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification
    Eric D Hsi
    Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Clin Lymphoma 5:89-97. 2004
    ..This review will focus on the features of primary cutaneous B-cell lymphomas, compare and contrast areas of discordance between the WHO and EORTC systems, and outline areas for further investigation...
  7. ncbi request reprint Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologist
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Pathol Lab Med 126:902-8. 2002
    ....
  8. ncbi request reprint Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Br J Haematol 120:1017-25. 2003
    ..Prospective trials are required to determine more precisely the prognostic significance of absolute expression levels in fresh CLL cells...
  9. ncbi request reprint The leukemias of mature lymphocytes
    Eric D Hsi
    Section of Hematopathology, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 23:843-71. 2009
    ..In this article, the major clinical, morphologic, phenotypic, and molecular genetic features of the mature B- and T-cell leukemias are reviewed, and differential diagnostic considerations are discussed...
  10. pmc Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:2081-90. 2008
    ..High Ki67 (>35%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study...
  11. doi request reprint Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
    Leuk Lymphoma 49:1668-80. 2008
    ..This manuscript reviews recent advances in our understanding of the pathobiology of cHL with an emphasis on biologic prognostic markers...
  12. ncbi request reprint A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Pathol Lab Med 128:863-8. 2004
    ..The clinical significance of this practice is not known...
  13. ncbi request reprint Update in the pathologic features of mature B-cell and T/NK-cell leukemias
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Diagn Pathol 20:180-95. 2003
    ..This in turn provides better information for clinicians to select proper therapy and determine prognosis. The characteristic pathologic features of these disorders are reviewed...
  14. ncbi request reprint Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going?
    E D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Histochem Cytochem 49:1323-4. 2001
    ..Indeed, our "view" of diseases now includes a rudimentary understanding of the molecular genetic abnormalities present in the cells we study under the microscope...
  15. ncbi request reprint Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry
    E D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
    Adv Anat Pathol 8:218-39. 2001
    ..The following is a review of the current state of immunophenotyping for lymphoid neoplasms in fixed tissues...
  16. ncbi request reprint Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma
    S Yegappan
    Department of Clinical Pathology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Mod Pathol 14:1147-56. 2001
    ..Cutaneous manifestations of AL are common; however, it appears to be a systemic lymphoma. Although often fatal, patients with AL who are diagnosed early and treated with chemotherapy may achieve remission...
  17. ncbi request reprint Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically
    J L Frater
    Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44106, USA
    Am J Clin Pathol 116:655-64. 2001
    ..aCLL can be distinguished from typical CLL morphologically, clinically, and immunophenotypically. Atypical morphologic features in CLL seem to be a marker of aggressive clinical behavior...
  18. ncbi request reprint Follicular lymphoma with marginal zone differentiation: microdissection demonstrates the t(14;18) in both the follicular and marginal zone components
    S Yegappan
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mod Pathol 14:191-6. 2001
    ....
  19. ncbi request reprint Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features
    I Mirza
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 20:647-55. 2002
    ..The aim of this study was to further characterize PCFL in a large series from North America...
  20. ncbi request reprint Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience
    P Ramalingam
    Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
    Mod Pathol 15:647-56. 2002
    ..Although the incidence is low, careful early monitoring of lung transplantation patients is warranted because of the poor prognosis of patients developing this complication...
  21. ncbi request reprint Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytes
    J L Frater
    Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
    Diagn Mol Pathol 10:214-22. 2001
    ..FISH can be performed successfully on archival single-cell preparations (touch preparations or gravity preparations) when fresh tissue is unavailable. No discordant or false-positive cases were identified...
  22. ncbi request reprint Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice
    A Ormsby
    Department of Anatomic Pathology and Dermatology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Am Acad Dermatol 45:405-13. 2001
    ..CONCLUSION: In the diagnosis of MF, detection of CD7 deletion and monoclonal TCR rearrangements can be successfully performed in a cost-effective, timely fashion using routine formalin-fixed paraffin-embedded biopsy specimens...
  23. ncbi request reprint Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma
    Mohamad A Hussein
    Cleveland Clinic Myeloma Research Program, Cleveland Clinic Foundation, OH 44195, USA
    Mayo Clin Proc 81:889-95. 2006
    ..To evaluate the efficacy and safety of adding thalidomide to the pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone (DVd) regimen for multiple myeloma...
  24. ncbi request reprint Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
    S D Smith
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:239-43. 2007
    ..Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed...
  25. ncbi request reprint Is there a role for folate determinations in current clinical practice in the USA?
    T Latif
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Lab Haematol 26:379-83. 2004
    ..We conclude that determination of serum folate level infrequently led to appropriate folate replacement therapy. Moreover, even when suspected, true folic acid deficiency is rare and clinical indications are not helpful in diagnosis...
  26. ncbi request reprint Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML
    Anjali S Advani
    Taussig Cancer Center, Leukemia Program, The Cleveland Clinic CCF, Cleveland, OH 44195, USA
    Leuk Res 32:913-8. 2008
    ..Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials...
  27. ncbi request reprint OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia
    Anjali S Advani
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Lymphoma 51:606-12. 2010
    ..10, p = 0.036) and a trend toward a worse OS (HR 1.10, p = 0.063). OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2. These results will need to be validated prospectively...
  28. ncbi request reprint A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
    Mohamad A Hussein
    Myeloma Research Program, Cleveland Clinic Taussig Center, Cleveland, Ohio 44195, USA
    Cancer 95:2160-8. 2002
    ..This Phase II study evaluates combination pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone in MM patients...
  29. doi request reprint A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Res 34:1622-6. 2010
    ..The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective...
  30. pmc Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
    K A Blum
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Ann Oncol 21:2246-54. 2010
    ....
  31. pmc Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
    J W Sweetenham
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Ann Oncol 21:1196-202. 2010
    ..The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy...
  32. doi request reprint Phosphoproteins and the dawn of functional phenotyping
    J Bodo
    Department of Clinical Pathology, Cleveland Clinic, OH 44195, USA
    Pathobiology 78:115-21. 2011
    ..However, phosphoproteins are extremely labile, a likely explanation for inconsistent or contradictory reports. Thus, the development of new paradigms for tissue handling, immunostaining, and quality control are needed...
  33. pmc Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis
    Sarah L Ondrejka
    Department of Clinical Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Haematologica 96:1121-7. 2011
    ..We report a series of leukemic phase mantle cell lymphomas with a non-progressive or slowly progressive course...
  34. doi request reprint Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma
    Xiuyan Xie
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Mod Pathol 21:653-9. 2008
    ..Characterizing PCLBCLs with markers of B-cell maturation stage is a useful framework for studying, classifying, and clinically stratifying these lymphomas...
  35. ncbi request reprint Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome
    Stephen J Sup
    Department of Clinical Pathology, L 11, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, USA
    J Clin Oncol 23:3773-9. 2005
    ..To date, there is no consensus on biologic markers that add value to these parameters...
  36. ncbi request reprint The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics
    Wouter Korver
    Nuvelo, Inc, San Carlos, CA, USA
    Br J Haematol 137:307-18. 2007
    ..Taken together, these results demonstrate NTB-A as a potential new target for immunotherapy of leukaemia and lymphomas...
  37. ncbi request reprint The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression
    Todd W Kelley
    Department of Clinical Pathology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Am J Clin Pathol 128:958-65. 2007
    ..This demonstrates the importance of evaluating tumor cell markers and the tumor immune infiltrate when considering biologic prognostic markers in cHL...
  38. ncbi request reprint TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage
    Marco Herling
    Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 31:1123-9. 2007
    ..Therefore, TCL1 expression can be used diagnostically as an indicator of the differentiation stage of a given B-cell tumor...
  39. ncbi request reprint Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies
    Xiaoxian Zhao
    Department of Clinical Pathology, United States
    Leuk Res 32:275-85. 2008
    ..The discovery of apoptotic pathways that can be manipulated by proteasome inhibition provides rationale for the combination of bortezomib and agents such as TRAIL in CHL treatment...
  40. doi request reprint High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlati
    Raymond Lai
    Leuk Lymphoma 49:1202-5. 2008
  41. pmc Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Blood 107:4207-13. 2006
    ..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
  42. ncbi request reprint Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation
    Sarah E Gibson
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Clin Pathol 126:916-24. 2006
    ..Although OCT-2 and BOB.1 were not associated with PAX5 expression, we report expression of OCT-2 in AML with myelomonocytic/monocytic maturation and BOB.1 in normal hematopoietic elements...
  43. ncbi request reprint Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival
    James R Cook
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Clin Pathol 125:615-24. 2006
    ..005). This report shows for the first time that cyclin D1 immunohistochemical analysis can provide prognostic information in plasma cell myeloma...
  44. pmc Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival
    Yasodha Natkunam
    Department of Pathology, Stanford University School of Medicine, CA, USA
    Blood 109:298-305. 2007
    ..The association with improved OS in univariate but not multivariate analysis suggests that HGAL expression is related to known clinical parameters of improved survival...
  45. ncbi request reprint Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases
    Thomas A Hembury
    Department of Clinical Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Clin Pathol 117:574-80. 2002
    ..We conclude that primary cutaneous DLBCL usually occurs in elderly patients with a male predominance. Recurrences are common, but death of disease is rare...
  46. ncbi request reprint MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Clin Pathol 125:776-82. 2006
    ..Stage showed borderline significance in OS (P = .08). MAL expression seems to identify a subset of cHL with an adverse outcome and provides additional evidence for a link between cHL and MLBL...
  47. ncbi request reprint Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18
    Marek Skacel
    Department of Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Diagn Mol Pathol 11:75-82. 2002
    ..Because of the relatively low frequency of MSI in the high-grade B-cell lymphomas of the stomach, this feature cannot be used to reliably discriminate between the histologic types of extranodal diffuse large B-cell lymphoma...
  48. ncbi request reprint CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    Eric D Hsi
    Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Cancer Res 14:2775-84. 2008
    ....
  49. ncbi request reprint Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F
    Sarah E Gibson
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Hum Pathol 39:1111-4. 2008
    ..Abnormal nuclear megakaryocytic staining for pSTAT5 expression, previously associated with the JAK2 V617F mutation, is also associated with MPL W515L, likely reflecting activation of the JAK-STAT signaling pathway...
  50. ncbi request reprint Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis
    Todd W Kelley
    Department of Clinical Pathology, L11, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
    Leuk Res 28:845-50. 2004
    ..27 fold (+/-2.57) increase in the percentage of apoptotic cells versus untreated controls. These data indicate that bortezomib has in vitro activity in CLL and support further investigations of this promising new drug...
  51. ncbi request reprint Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma
    Rajiv M Patel
    Division of Pathology and Laboratory Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mod Pathol 17:456-60. 2004
    ..As such, it is an extremely useful tool for differentiating between Kaposi sarcoma and other vascular and nonvascular spindle cell lesions, which do not express human herpes virus 8 latent nuclear antigen-1...
  52. ncbi request reprint Molecular pathology testing of tissues fixed in prefer solution
    Raymond R Tubbs
    Am J Surg Pathol 28:417-9. 2004
  53. ncbi request reprint Properties of the mantle cell and mantle cell lymphoma
    John L Frater
    Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois, USA
    Curr Opin Hematol 9:56-62. 2002
    ..The authors summarize these new advances in the understanding of the biology of the mantle cell and newer ancillary techniques in the diagnosis of lymphomas arising from this cell type...
  54. ncbi request reprint Detection of mature T-cell leukemias by flow cytometry using anti-T-cell receptor V beta antibodies
    Rose C Beck
    Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Am J Clin Pathol 120:785-94. 2003
    ....
  55. ncbi request reprint Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infant
    Jacqueline K Trupiano
    Department of Pathology, Cleveland Clinic Foundation, OH 44195, USA
    J Cutan Pathol 29:107-12. 2002
    ..We report a case of primary cutaneous lymphoblastic lymphoma (LBL) presenting in an 8-week-old infant...
  56. ncbi request reprint Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma
    Rose C Beck
    Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
    Diagn Mol Pathol 12:14-20. 2003
    ..Automated CISH is useful in detecting light chain expression in paraffin sections and appeared superior to IHC for light chain detection in PC dyscrasias and B cell non-Hodgkin lymphomas, predominantly due to lack of background staining...
  57. ncbi request reprint LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
    Yasodha Natkunam
    Department of Pathology, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 26:447-54. 2008
    ..Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab...
  58. ncbi request reprint The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study
    David M Dorfman
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arch Pathol Lab Med 130:779-82. 2006
    ..Consequently, correct identification of c-Kit expression is important for the diagnosis and treatment of GISTs...
  59. ncbi request reprint The correlation dimension identifies B-cell immunoglobulin light chain restriction in peripheral blood flow cytometry data
    Nicholas T Wongchaowart
    Department of Clinical Pathology, Cleveland Clinic, Foundation, Cleveland, OH 44195, USA
    Am J Clin Pathol 125:600-7. 2006
    ..The D2 can identify LCR in peripheral blood flow cytometry data. It offers operator-independent data analysis and may be useful in objectively quantifying differences in data distribution...
  60. ncbi request reprint Simian virus 40 in posttransplant lymphoproliferative disorders
    Regis A Vilchez
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Hum Pathol 37:1130-6. 2006
    ..These results suggest that SV40 may be associated with a small subset of PTLD cases. Additional studies are needed to determine the role of SV40 in EBV-negative PTLD...
  61. ncbi request reprint Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Surg Pathol 31:106-12. 2007
    ..Thus, the combined nuclear localization of c-Rel and the cellular expression of TRAF1 is a highly specific (specificity=98%) means to distinguish PMLBCL from DLBCL that is readily applicable to routine surgical pathology practice...
  62. pmc T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6
    XiaoQing Lu
    Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Mol Cell Biol 27:2166-79. 2007
    ....
  63. ncbi request reprint Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation
    Samer Aboudola
    Department of Clinical Pathology and Laboratory Medicine, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 31:233-9. 2007
    ..Phosphoprotein detection represents a new area for diagnostic pathology that exploits specific functional characteristics of cells within the context of a tissue section...
  64. ncbi request reprint Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American Pathologists
    Marina N Nikiforova
    Department of Pathology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Arch Pathol Lab Med 131:185-9. 2007
    ....
  65. ncbi request reprint Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:97-103. 2007
    ..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule...
  66. ncbi request reprint Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics
    Roger A Warnke
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5324, USA
    Am J Clin Pathol 127:511-27. 2007
    ....
  67. ncbi request reprint Response to Pantanowitz et al. Regarding our paper on the utility of the detection of HHV-8 LNA-1 by immunohistochemistry in the diagnosis of Kaposi's sarcoma
    Rajiv M Patel
    Mod Pathol 18:1011-2. 2005
  68. ncbi request reprint Clinical laboratory reports in molecular pathology
    Margaret L Gulley
    Department of Pathology, 913 Brinkhous Bullitt Bldg, University of North Carolina, Chapel Hill, NC 27599 7525, USA
    Arch Pathol Lab Med 131:852-63. 2007
    ..The recent introduction of array technology has added another layer of complexity involving massive parallel analysis of multiple genes, transcripts, or proteins...
  69. ncbi request reprint Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation
    Tania Zuluaga Toro
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Br J Haematol 139:31-40. 2007
    ..Nuclear pSTAT5 in MCs from SM reflects abnormal TK activation. We propose nuclear pSTAT5 positivity in MCs as an additional minor phenotypic criterion for diagnosis of SM in future World Health Organization classification schemes...
  70. ncbi request reprint Podocalyxin: a marker of blasts in acute leukemia
    Todd W Kelley
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Clin Pathol 124:134-42. 2005
    ..Therefore, podocalyxin seems to complement CD34 as a useful hematopoietic blast marker. The physiologic role of podocalyxin in leukemic blasts remains unknown...
  71. ncbi request reprint Advances in the diagnosis and classification of chronic lymphoproliferative disorders
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Cancer Treat Res 121:145-65. 2004
    ..Insight into the biology of these diseases also may provide new therapeutic targets in the future...
  72. ncbi request reprint t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas
    Nicholas T Wongchaowart
    Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Cutan Pathol 33:286-92. 2006
    ..However, the incidence of IGH/MALT1 translocations in these forms of cutaneous lymphoma remains unclear...

Research Grants1

  1. Characterization of Methods for Preservation of Phosphoproteins in fixed tissues
    Eric Hsi; Fiscal Year: 2007
    ..Furthermore, control material with defined relative expression levels of many PPs will result from this application and allow laboratories to assess performance of their individual assays. ..